A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer

Human epidermal growth factor receptor 2 (HER2)-targeted vaccines are under development, but have so far demonstrated only modest clinical efficacy. Additionally, there has been a lack of adequate safety assessment in large-scale prospective clinical trials. Therefore, we performed a meta-analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Ricardo, Zaman, Saif, Sharpe, Susan, Helenowski, Irene, Shaw, Colleen, Han, Hyo, Soliman, Hatem, Czerniecki, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338114/
https://www.ncbi.nlm.nih.gov/pubmed/30679903
http://dx.doi.org/10.2147/DDDT.S188925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338114/
https://www.ncbi.nlm.nih.gov/pubmed/30679903
http://dx.doi.org/10.2147/DDDT.S188925

Ejemplares similares